Deepa quotes the FDA: CDER communication with sponsors to implement SSDC (Selective Safety Data Collection)in appropriately identified trials will result in improved understanding of its real-world applicability, demonstration of its ability to facilitate efficient clinical trials, identification of potential challenges that programs encounter and ways to address those challenges, and promotion of best practices. As more sponsors pilot (Selective Safety Data Collection) SSDC in diverse therapeutic areas, the industry is gradually building an evidence base for: Improved patient retention through lower burden Reduced costs from fewer site visits and labs Faster recruitment due to simplified protocols Streamlined global trials enabled through regulatory harmonization Initiatives like FDAs Center for Clinical Trial Innovation (C3TI) Demonstration Program aim to promote cross-stakeholder collaboration and accelerate the uptake of (Selective Safety Data Collection) SSDC in industry (FDA C3TI, 2024)
Figure 2 Adrenaline and noradrenaline act as ligands for ARs, which belong to G protein-coupled receptors (GPCRs) ( 1A , 1B , 1D , 2A , 2B , 2C , 1 , 2 , and 3 , each with unique properties, specificity, and tissue distribution ( 1 -ARs are coupled with G q protein, which activates phospholipase C, leading to PIP2 (phosphatidylinositol 4,5-bisphosphate) hydrolysis into IP3 (inositol 1,4,5-triphosphate) and DAG (diacylglycerol) ( 2 -ARs are coupled with G i , suppressing adenylyl cyclase activity and decreasing intracellular cAMP (cyclic adenosine monophosphate) levels, whereas -ARs, coupled with G s , stimulate adenylyl cyclase activity, resulting in cAMP increase ( Table 1 ) ( Table 1 AR subtypes and their preferred ligands
427 FtMt is responsible for transporting and storing iron from the cytoplasm to the mitochondria, thereby reducing the production of cytoplasmic ROS
10.1080/02770903.2020.1781166 J Asthma
